Endometrial cancer risk and survival by tumor MMR status

다국어 초록 (Multilingual Abstract)

Objective: The risk of developing endometrial cancer (EC) and/or survival following a diagnosis of EC might differ by tumor DNA mismatch repair (MMR) status. We assessed the association between tumor MMR status (classified as MMR-proficient, somatic MMR-deficient, germline MMR-deficient) and the risk of developing EC and survival following a diagnosis of EC.
Methods: We analyzed data from women who participated in the Australian National Endometrial Cancer Study (ANECS) conducted between 2005 and 2007. Risk analyses (698 cases/691 population controls) utilized sociodemographic and lifestyle information obtained from telephone interviews at recruitment. For survival analyses (728 cases), patients' clinical data was abstracted from medical records, and survival data were obtained via linkage with the Australian National Death Index. We used logistic regression analysis to evaluate the associations between tumor MMR status and EC risk, and proportional hazards models to perform survival analyses with adjustment of known prognostic factors.
Results: Established risk factors for EC did not differ significantly by tumor MMR status. In analyses including all EC subtypes, overall and EC-specific survival did not differ by tumor MMR status. Among women with the most common endometrioid subtype, EC-specific survival was worse for women with somatic MMR-deficient EC compared to women with MMR-proficient EC (hazard ratio [HR]=2.18; 95% confidence interval [CI]=1.19–4.01).
Conclusion: The risk of EC is not associated with MMR status. Accurate separation of germline from somatic causes of MMR deficiency suggests that patients with endometrioid subtype somatic MMR-deficient tumors have poorer EC-specific survival than those with MMR-proficient tumors, after accounting for other prognostic factors.

참고문헌 (Reference)

1 Watkins JC, "Universal screening for mismatch-repair deficiency in endometrial cancers to identify patients with Lynch syndrome and Lynchlike syndrome" 36 : 115-127, 2017

2 Boland CR, "The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside" 7 : 41-52, 2008

3 Huang DW, "Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources" 4 : 44-57, 2009

4 Buchanan DD, "Reply to J. Moline et al." 32 : 2278-2279, 2014

5 Mackay HJ, "Prognostic value of microsatellite instability (MSI) and PTEN expression in women with endometrial cancer: results from studies of the NCIC Clinical Trials Group (NCIC CTG)" 46 : 1365-1373, 2010

6 Tangjitgamol S, "Prevalence and prognostic role of mismatch repair gene defect in endometrial cancer patients" 39 : 1010428317725834-, 2017

7 Stelloo E, "Practical guidance for mismatch repair-deficiency testing in endometrial cancer" 28 : 96-102, 2017

8 Hecht JL, "Molecular and pathologic aspects of endometrial carcinogenesis" 24 : 4783-4791, 2006

9 Love MI, "Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2" 15 : 550-, 2014

10 Diaz-Padilla I, "Mismatch repair status and clinical outcome in endometrial cancer: a systematic review and meta-analysis" 88 : 154-167, 2013

11 Zighelboim I, "Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type" 25 : 2042-2048, 2007

12 Matthews KS, "Lynch syndrome in women less than 50 years of age with endometrial cancer" 111 : 1161-1166, 2008

13 Najdawi F, "Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy" 49 : 457-464, 2017

14 Ruiz I, "Lack of association between deficient mismatch repair expression and outcome in endometrial carcinomas of the endometrioid type" 134 : 20-23, 2014

15 Liao C, "Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies" 135 : 163-171, 2014

16 Cancer Genome Atlas Research Network, "Integrated genomic characterization of endometrial carcinoma" 497 : 67-73, 2013

17 Kanopiene D, "Impact of microsatellite instability on survival of endometrial cancer patients" 50 : 216-221, 2014

18 Pakish JB, "Immune microenvironment in microsatellite-instable endometrial cancers: hereditary or sporadic origin matters" 23 : 4473-4481, 2017

19 Amankwah EK, "Hormonal and reproductive risk factors for sporadic microsatellite stable and unstable endometrial tumors" 22 : 1325-1331, 2013

20 Nead KT, "Evidence of a causal association between insulinemia and endometrial cancer: a mendelian randomization analysis" 107 : djv178-, 2015

21 Cosgrove CM, "Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival" 146 : 588-595, 2017

22 Garg K, "Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset" 33 : 1869-1877, 2009

23 Spurdle AB, "Endometrial cancer gene panels: clinical diagnostic vs research germline DNA testing" 30 : 1048-1068, 2017

24 Shikata K, "Diabetes mellitus and cancer risk: review of the epidemiological evidence" 104 : 9-14, 2013

25 Masafumi Kato, "DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers" 대한부인종양학회 26 (26): 40-45, 2015

26 Cohn DE, "Correlation between patient weight and defects in DNA mismatch repair: is this the link between an increased risk of previous cancer in thinner women with endometrial cancer?" 18 : 136-140, 2008

27 Benjamini Y, "Controlling the false discovery rate: a practical and powerful approach to multiple testing" 57 : 289-300, 1995

28 McMeekin DS, "Clinicopathologic significance of mismatch repair defects in endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study" 34 : 3062-3068, 2016

29 Black D, "Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma" 24 : 1745-1753, 2006

30 Shikama A, "Clinicopathologic implications of DNA mismatch repair status in endometrial carcinomas" 140 : 226-233, 2016

31 Buchanan DD, "Clinical problems of colorectal cancer and endometrial cancer cases with unknown cause of tumor mismatch repair deficiency (suspected Lynch syndrome)" 7 : 183-193, 2014

32 Grzankowski KS, "Clinical and pathologic features of young endometrial cancer patients with loss of mismatch repair expression" 126 : 408-412, 2012

33 Ferlay J, "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012" 136 : E359-E386, 2015

34 McCourt CK, "Body mass index: relationship to clinical, pathologic and features of microsatellite instability in endometrial cancer" 104 : 535-539, 2007

35 Huang DW, "Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists" 37 : 1-13, 2009

36 Amankwah EK, "Anthropometric measures and the risk of endometrial cancer, overall and by tumor microsatellite status and histological subtype" 177 : 1378-1387, 2013